Plain-English translation of NCT05951751 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The TRI-MOM program is testing a simplified, coordinated screening strategy to identify and treat three serious infections—HIV, syphilis, and hepatitis B—in pregnant women at antenatal clinics. The goal is to prevent these infections from passing to babies during pregnancy and birth. Researchers will train healthcare workers to use quick, affordable tests and provide treatment to women who test positive.
Mother-to-child transmission of these three infections remains a major health problem in West Africa. This study exists to see whether a coordinated screening and treatment approach using simple, low-cost rapid tests can be effectively integrated into existing maternal health services and reduce the number of babies born with these infections.
If you join this study, you would have screening tests for HIV, syphilis, and hepatitis B during your postnatal visit at one of the participating clinics. If you test positive for any of these infections, you would receive assessment and treatment. The study also includes education about how these infections can be passed to babies and support to help you manage your health. Researchers will follow some women with positive results over time to see how well the screening and treatment program works.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Burkina Faso
The Gambia
Collaborators
Centre Muraz, Medical Research Council
Enrollment target
~2,800 participants
Started
March 2024
Primary completion
May 2025
Sex
Female only
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lauren Perieres, PhD
UMR 1252 SESSTIM